Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
NCT ID: NCT04178967
Last Updated: 2023-05-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
445 participants
INTERVENTIONAL
2019-10-29
2022-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
NCT04146363
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
NCT04250337
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
NCT03443024
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
NCT06280716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Induction Period (Baseline-Week 16):
Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
Maintenance Period (Week 16-Week 52):
Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50.
Placebo
Subcutaneous Injection
Lebrikizumab Q2W
Induction Period (Baseline-Week 16):
500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.
Maintenance Period (Week 16-Week 52):
One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and Week 18.
One 250 mg Lebrikizumab SC injection Q2W until Week 50.
Lebrikizumab
Subcutaneous injection
Lebrikizumab Q4W
Maintenance Period (Week 16-Week 52):
One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and two placebo SC injections on Week 18.
One 250 mg Lebrikizumab SC injection Every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.
One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.
Lebrikizumab
Subcutaneous injection
Placebo
Subcutaneous Injection
Escape Arm (Lebrikizumab Q2W)
Maintenance Period (Week 16-Week 52):
Participants who require topical or systemic rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score \<50% of baseline), will be eligible for the Escape Arm.
Lebrikizumab
Subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lebrikizumab
Subcutaneous injection
Placebo
Subcutaneous Injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit
* Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit
* Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit
* ≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit
* History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable
Exclusion Criteria
* Treatment with topical corticosteroids, calcineurin inhibitors or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit
* Treatment with any of the following agents within 4 weeks prior to the baseline visit:
* Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
* Phototherapy and photochemotherapy (PUVA) for AD
* Treatment with the following prior to the baseline visit:
* An investigational drug within 8 weeks or within 5 half-lives (if known) of baseline, whichever is longer
* Cell-depleting biologics, including to rituximab, within 6 months of baseline
* Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever is longer
* Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study
* Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma
* Evidence of active acute or chronic hepatitis
* History of human immunodeficiency virus (HIV) infection or positive HIV serology
* History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin
* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Dermira, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigate MD
Scottsdale, Arizona, United States
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas, United States
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California, United States
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States
Woodward Centre
Fresno, California, United States
Dermatology Research Associates
Los Angeles, California, United States
LA Universal Research Center, INC
Los Angeles, California, United States
University Clinical Trials, Inc.
San Diego, California, United States
San Luis Dermatology & Laser Clinic
San Luis Obispo, California, United States
Clinical Physiology Associates, Clinical Study Center
Fort Myers, Florida, United States
Direct Helpers Medical Center
Hialeah, Florida, United States
The Community Research of South Florida
Hialeah, Florida, United States
Solutions Through Advanced Research, Inc.
Jacksonville, Florida, United States
Georgia Pollens Clinical Research Centers, Inc
Albany, Georgia, United States
Marietta Dermatology Clinical Research
Marietta, Georgia, United States
Advanced Medical Research
Sandy Springs, Georgia, United States
Arlington Dermatology
Rolling Meadows, Illinois, United States
NorthShore University HealthSystem
Skokie, Illinois, United States
Kansas City Dermatology, PA
Overland Park, Kansas, United States
Meridian Clinical Research
Baton Rouge, Louisiana, United States
ActivMed Practices and Research
Beverly, Massachusetts, United States
Tufts Medical Center
Boston, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
Clarkston Skin Research
Clarkston, Michigan, United States
Associated Skin Care Specialists
Fridley, Minnesota, United States
Central Dermatology PC
St Louis, Missouri, United States
Forest Hills Dermatology Group
Kew Gardens, New York, United States
OnSite Clinical Solutions
Charlotte, North Carolina, United States
Wilmington Dermatology Center
Wilmington, North Carolina, United States
Dermatology and Skin Surgery Center
Exton, Pennsylvania, United States
DermDOX
Hazleton, Pennsylvania, United States
Peak Research LLC
Upper Saint Clair, Pennsylvania, United States
Dermatology & Laser Center of Charleston
Charleston, South Carolina, United States
Palmetto Clinical Trial Services
Greenville, South Carolina, United States
Arlington Research Center, Inc
Arlington, Texas, United States
Innovate Research, LLC
Fort Worth, Texas, United States
Austin Institute for Clinical Research
Pflugerville, Texas, United States
University of Utah MidValley Dematology
Murray, Utah, United States
Virginia Clinical Research, Inc.
Norfolk, Virginia, United States
Dermatology Associates
Seattle, Washington, United States
DCC Sveti Georgi
Plovdiv, , Bulgaria
Diagnostic and Consultation Center 14
Sofia, , Bulgaria
Alexandrovska University Hospital
Sofia, , Bulgaria
Euro Derma clinic
Sofia, , Bulgaria
Military Medical Academy
Sofia, , Bulgaria
Medical centre Alitera-Med EOOD
Sofia, , Bulgaria
Dr. Chih-ho Hong Medical Inc.
Surrey, British Columbia, Canada
Simcoderm Medical & Surgical Dermatology Centre
Barrie, Ontario, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
North York Research Inc.
North York, Ontario, Canada
Ottawa Allergy Research Corp
Ottawa, Ontario, Canada
K. Papp Clinical Research
Waterloo, Ontario, Canada
Derma-Study-Center Friedrichshafen GmbH
Friedrichshafen, Baden-Wurttemberg, Germany
Studienzentrum Dr.Beate Schwarz
Langenau, Baden-Wurttemberg, Germany
Hautarztpraxis am Löwenmarkt
Stuttgart, Baden-Wurttemberg, Germany
licca Fachklinik
Augsburg, Bavaria, Germany
Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH
Darmstadt, Hesse, Germany
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Frankfurt am Main, Hesse, Germany
Elbe Klinikum Buxtehude
Buxtehude, Lower Saxony, Germany
Klinische Forschung Osnabrück
Osnabrück, Lower Saxony, Germany
Fachklinik Bad Bentheim
Bad Bentheim, North Rhine-Westphalia, Germany
Hautzentrum im Jahrhunderthaus
Bochum, North Rhine-Westphalia, Germany
Universitätsklinikum Münster
Münster, North Rhine-Westphalia, Germany
SIBAmed Studienzentrum GmbH & Co. KG
Leipzig, Saxony, Germany
Universität Leipzig - Universitätsklinikum
Leipzig, Saxony, Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, Schleswig-Holstein, Germany
Praxis Dr. Michael Dietlen
Augsburg, , Germany
Charité Universitätsmedizin Berlin Campus Buch
Berlin, , Germany
ISA GmbH
Berlin, , Germany
Praxis für Ganzheitliche Dermatologie im Ärztehaus
Berlin, , Germany
Universitätsklinikum Hamburg
Hamburg, , Germany
TFS Trial Form Support GmbH
Hamburg, , Germany
Clinica De Enfermedades Cronicas y Procedimientos Especiales
Morelia, Michoacan Morelia, Mexico
Derma Norte del Bajío, S.C.
Aguascalientes, , Mexico
National University Hospital
Singapore, , Singapore
Singapore General Hospital
Singapore, , Singapore
Kk Women'S and Childrens Hospital
Singapore, , Singapore
National Skin Centre NSC
Singapore, , Singapore
Kaohsiung Chang Gung Memorial Hospital
Niaosong Dist, Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Institutional Review B
Kaohsiung City, , Taiwan
Taipei Medical University- Shuang Ho Hospital
New Taipei City, , Taiwan
Chung Shan Medical University Hospital
Taichung, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital - Linkou
Taoyuan, , Taiwan
Municipal Healthcare Institution Kharkiv City Dermatoverenologic Dispensary N2
Kharkiv, , Ukraine
Rivne Regional Dermatology and Venereology Dispensary
Rivne, , Ukraine
Treatment-diagnostic center PE "Asclepius"
Uzhhorod, , Ukraine
Community Institution Zaporizhzhya Regional Dermatovenereology Clinical Hospital of Zaporizhzhya Regional Council
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Guttman-Yassky E, Sun Z, Mena LR, Hahn N, Nickoloff BJ, Preuss C, Siu K, Natalie CR, Gallo G, Wolf E, Eyerich K, Aparici M, Benschop RJ, Okragly A. Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2025 Sep;15(9):2595-2614. doi: 10.1007/s13555-025-01481-4. Epub 2025 Jul 15.
Simpson E, Fernandez-Penas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K, Agell H, Casillas M, Ding Y, Yang FE, Pierce E, Bieber T. Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2). Adv Ther. 2025 Jan;42(1):132-143. doi: 10.1007/s12325-024-02974-y. Epub 2024 Sep 9.
Silverberg JI, Wollenberg A, Stein Gold L, Del Rosso J, Yosipovitch G, Lio P, Carrascosa JM, Gallo G, Ding Y, Xu Z, Casillas M, Pierce E, Agell H, Stander S. Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment. Dermatol Ther (Heidelb). 2024 Aug;14(8):2249-2260. doi: 10.1007/s13555-024-01226-9. Epub 2024 Aug 10.
Yosipovitch G, Lio P, Legat FJ, Chovatiya R, Deleuran M, Pierce E, Casillas M, Ding Y, Yang FE, Bardolet L, Stander S. Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks. Dermatol Ther (Heidelb). 2024 Aug;14(8):2171-2180. doi: 10.1007/s13555-024-01225-w. Epub 2024 Jul 13.
Lio PA, Armstrong A, Gutermuth J, Nosbaum A, Sofen H, Gil EG, Casillas M, Chen S, Sun L, Pierce E, Elmaraghy H, Dawson Z, Torres T. Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 Jul;14(7):1929-1943. doi: 10.1007/s13555-024-01199-9. Epub 2024 Jun 26.
Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Salle D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI. Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 May;14(5):1145-1160. doi: 10.1007/s13555-024-01158-4. Epub 2024 May 3.
Soung J, Stander S, Gutermuth J, Pau-Charles I, Dawson Z, Yang FE, Sun L, Pierce E, Elmaraghy H, Stein-Gold L. Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials. J Dermatolog Treat. 2024 Dec;35(1):2329240. doi: 10.1080/09546634.2024.2329240. Epub 2024 Apr 28.
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox M, Garcia Gil E, Silverberg JI. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022.
Silverberg JI, Guttman-Yassky E, Thaci D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-002933-12
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
J2T-DM-KGAC
Identifier Type: OTHER
Identifier Source: secondary_id
DRM06-AD05
Identifier Type: OTHER
Identifier Source: secondary_id
17802
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.